Terms: = Ovarian cancer AND SYK, P43405, 6850, ENSG00000165025
21 results:
1. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract] [Full Text] [Related]
2. Activation of the Innate Immune Checkpoint CLEC5A on Myeloid Cells in the Absence of Danger Signals Modulates Macrophages' Function but Does Not Trigger the Adaptive T Cell Immune Response.
Tosiek MJ; Groesser K; Pekcec A; Zwirek M; Murugesan G; Borges E
J Immunol Res; 2022; 2022():9926305. PubMed ID: 35252461
[TBL] [Abstract] [Full Text] [Related]
3. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract] [Full Text] [Related]
4. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
[TBL] [Abstract] [Full Text] [Related]
5. Elevated Serum Human Epididymis Protein 4 Is Associated With Disease Activity and Systemic Involvements in Primary Sjögren's Syndrome.
Chen J; Sun F; Bao H; Liang L; Zhan M; Yao H; He J; Liu Y
Front Immunol; 2021; 12():670642. PubMed ID: 34248951
[TBL] [Abstract] [Full Text] [Related]
6. Transcriptome sequencing identifies genes associated with invasion of ovarian cancer.
Peng X; Yu M; Chen J
J Int Med Res; 2020 Sep; 48(9):300060520950912. PubMed ID: 32878513
[TBL] [Abstract] [Full Text] [Related]
7. [High Expression Level of SP1, CSF1R, and PAK1 Correlates with Sensitivity of Leukemia Cells to the Antibiotic Mithramycin].
Vagapova ER; Lebedev TD; Tikhonova AD; Goikhman BV; Ivanenko KA; Spirin PV; Prassolov VS
Mol Biol (Mosk); 2020; 54(3):522-528. PubMed ID: 32492016
[TBL] [Abstract] [Full Text] [Related]
8. Design and optimization of orally spleen tyrosine kinase (syk) inhibitors for treatment of solid tumor.
Wang C; Wang X; Li Y; Wang T; Huang Z; Qin Z; Yang S; Xiang R; Fan Y
Bioorg Chem; 2020 Jan; 95():103547. PubMed ID: 31911307
[TBL] [Abstract] [Full Text] [Related]
9. Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Yu Y; Suryo Rahmanto Y; Shen YA; Ardighieri L; Davidson B; Gaillard S; Ayhan A; Shi X; Xuan J; Wang TL; Shih IM
EBioMedicine; 2019 Sep; 47():184-194. PubMed ID: 31492560
[TBL] [Abstract] [Full Text] [Related]
10. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China.
Zhang M; Zhang Y; Zhang L; Tian Q
Prog Mol Biol Transl Sci; 2019; 163():297-328. PubMed ID: 31030752
[TBL] [Abstract] [Full Text] [Related]
11. Expression of syk and MAP4 proteins in ovarian cancer.
Zhang S; Deen S; Storr SJ; Yao A; Martin SG
J Cancer Res Clin Oncol; 2019 Apr; 145(4):909-919. PubMed ID: 30737623
[TBL] [Abstract] [Full Text] [Related]
12. The syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract] [Full Text] [Related]
13. Inhibition of ovarian tumor cell invasiveness by targeting syk in the tyrosine kinase signaling pathway.
Yu Y; Suryo Rahmanto Y; Lee MH; Wu PH; Phillip JM; Huang CH; Vitolo MI; Gaillard S; Martin SS; Wirtz D; Shih IM; Wang TL
Oncogene; 2018 Jul; 37(28):3778-3789. PubMed ID: 29643476
[TBL] [Abstract] [Full Text] [Related]
14. Differences in C-type lectin receptors and their adaptor molecules in the peritoneal fluid of patients with endometriosis and gynecologic cancers.
Yeo SG; Won YS; Kim SH; Park DC
Int J Med Sci; 2018; 15(4):411-416. PubMed ID: 29511377
[TBL] [Abstract] [Full Text] [Related]
15. Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Park GB; Chung YH; Kim D
Oncol Rep; 2017 May; 37(5):3137-3145. PubMed ID: 28350104
[TBL] [Abstract] [Full Text] [Related]
16. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
Lan Z; Fu D; Yu X; Xi M
Fam Cancer; 2016 Apr; 15(2):221-30. PubMed ID: 26458935
[TBL] [Abstract] [Full Text] [Related]
17. Spleen Tyrosine Kinase Confers Paclitaxel Resistance in ovarian cancer.
Wei W; Birrer MJ
Cancer Cell; 2015 Jul; 28(1):7-9. PubMed ID: 26175410
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in ovarian cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract] [Full Text] [Related]
19. Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.
Sereni MI; Baldelli E; Gambara G; Deng J; Zanotti L; Bandiera E; Bignotti E; Ragnoli M; Tognon G; Ravaggi A; Meani F; Memo M; Angioli R; Liotta LA; Pecorelli SL; Petricoin E; Pierobon M
Proteomics; 2015 Jan; 15(2-3):365-73. PubMed ID: 25311472
[TBL] [Abstract] [Full Text] [Related]
20. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.
Jinawath N; Vasoontara C; Jinawath A; Fang X; Zhao K; Yap KL; Guo T; Lee CS; Wang W; Balgley BM; Davidson B; Wang TL; Shih IeM
PLoS One; 2010 Jun; 5(6):e11198. PubMed ID: 20585448
[TBL] [Abstract] [Full Text] [Related]
[Next]
